MedTrace Logo

A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab

NCT03336281 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 221

Last updated 2025-02-03

No results posted yet for this study

Summary

The primary purpose of this study is to describe the Psoriatic Arthritis (PsA) participant profiles depending on whether their disease is managed by a dermatologist or by a rheumatologist in routine practice.

Conditions

Interventions

DRUG

Ustekinumab

All participants will receive ustekinumab at study entry. Ustekinumab will not be provided by the sponsor. The treatment decision must have been taken by the investigator prior to, and independently of the participant's inclusion into the study following the standard clinical practice. Only data available from a participant's source medical records will be collected.

Sponsors & Collaborators

  • Janssen Cilag S.A.S.

    lead INDUSTRY

Principal Investigators

  • Janssen Cilag S.A.S., France Clinical Trial · Janssen Cilag S.A.S.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-25
Primary Completion
2020-04-07
Completion
2020-04-07

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03336281 on ClinicalTrials.gov